SYNLOGIC, INC.

SYNLOGIC, INC. Annual Report: A Pivotal Shift and Uncertain Future

SYNLOGIC, INC. has undergone a dramatic transformation over the past year, shifting from a biopharmaceutical developer to a company with no active operations. This summary provides a critical overview of its current state, highlighting the significant strategic changes and associated risks investors must understand.

Business Overview

SYNLOGIC, INC. has fundamentally altered its business model, moving away from its former focus as a biopharmaceutical company developing treatments for rare metabolic disorders.

• Drug Program Halted: In February 2024, the company halted development of its lead drug candidate, labafenogene marselecobac (SYNB1934), for Phenylketonuria (PKU). An internal review concluded the drug was unlikely to meet its primary goal of significantly reducing phenylalanine levels in patients. This decision, unrelated to safety concerns, effectively ended their primary research efforts.
• Cessation of R&D: Consequently, SYNLOGIC, INC. now has no active research and development programs or ongoing clinical trials. R&D expenditures for the nine months ended September 30, 2025, totaled a mere $16,000, a sharp decline from $37.5 million in the prior year, clearly demonstrating this strategic shift.
• Workforce Reduction: The company significantly reduced its workforce from approximately 100 employees at the end of 2023 to fewer than 10 by late 2024, reflecting the winding down of all operational activities.
• Strategic Reorientation: Seeking Alternatives: With its drug development pipeline discontinued, SYNLOGIC, INC. now focuses solely on identifying and executing a strategic transaction to "enhance stockholder value." The company actively explores various strategic alternatives, such as a merger with another entity, an outright sale, or an acquisition of new assets or businesses that could leverage its public company status.
• "Public Shell" Designation: In November 2025, Nasdaq designated SYNLOGIC, INC. a "public shell" due to its lack of significant ongoing business operations, minimal revenue, negligible R&D, and substantial employee reduction. The company confirmed this status, with primary ongoing expenses now limited to maintaining its public company reporting obligations, including legal, accounting, and administrative costs.

Financial Performance

The financial statements clearly reflect the company's dramatic shift and current operational status.

• No Revenue: For the nine months ended September 30, 2025, SYNLOGIC, INC. reported no revenue from operations. This marks a significant change from prior periods when the company incurred substantial R&D expenses pursuing its biopharmaceutical pipeline.
• Net Loss: The company reported a net loss of approximately $10.5 million for the nine months ended September 30, 2025. This loss, primarily from winding down operations, administrative costs, and severance payments, represents a significant reduction from prior periods due to the cessation of R&D activities.
• R&D Expenditures: R&D expenditures for the nine months ended September 30, 2025, totaled a mere $16,000, a substantial decrease from $37.5 million in the prior year. This reflects the complete halt of all drug development programs.

Management's Discussion and Analysis (MD&A) Highlights

Management's discussion highlights the critical strategic pivot and its financial implications.

• Operational Cessation and Cost Reduction: The decision to cease all biopharmaceutical development activities primarily drove the company's financial results for the reporting period. This led to a dramatic reduction in operating expenses, particularly R&D, historically the largest expenditure. The workforce reduction further lowered personnel costs.
• Strategic Alternatives Exploration: The company now focuses entirely on identifying and completing a strategic transaction. Management actively discusses options with potential partners, recognizing the critical need to leverage its public company status to create shareholder value.
• Impact of Nasdaq Delisting: Delisting from Nasdaq and subsequent trading on the OTC Pink Market reflect the company's "public shell" status. Management acknowledges the reduced liquidity and visibility of OTC trading, along with the increased administrative burden of maintaining public company reporting obligations without active revenue-generating operations.
• Liquidity and Capital Resources: Management focuses on conserving its remaining cash resources while pursuing strategic options. The current cash balance funds ongoing public company costs and supports the strategic transaction process. The company's ability to continue as a going concern depends directly on successfully executing a strategic transaction or securing additional funding.

Financial Health

As of September 30, 2025, the company's financial health reflects its transition to a non-operational entity.

• Cash Position: The company held approximately $14.2 million in cash and cash equivalents. This cash balance is critical for funding ongoing public company expenses and the strategic transaction process.
• Debt: The company reported minimal long-term debt as of the reporting date, reflecting its asset-light operational status after ceasing biopharmaceutical activities.
• Liquidity: With no revenue-generating operations, the company's liquidity depends primarily on its existing cash reserves. Management focuses on managing these reserves to cover administrative and public company costs while pursuing strategic alternatives.
• Shareholder Equity: Total shareholder equity stood at approximately $12.8 million.
• Market Capitalization: As of June 30, 2025, common stock held by non-affiliates had a market value of approximately $4.4 million, with shares trading around $1.27.

Future Outlook

SYNLOGIC, INC.'s future outlook depends entirely on the successful execution of its strategic reorientation.

• Uncertainty of Strategic Transaction: While discussions with potential partners continue, no guarantee exists that these discussions will lead to a definitive agreement, or that any potential transaction will be completed on favorable terms, or at all. The company has not provided a specific timeline for these efforts.
• Going Concern: The company's ability to continue as a going concern depends on successfully executing a strategic transaction or securing additional funding, which is not guaranteed. Without a successful transaction, the company may eventually liquidate its remaining assets.
• No Operational Guidance: As a "public shell" with no active operations, the company provides no traditional operational or financial guidance. The nature and success of any strategic transaction will determine its future trajectory.

Competitive Position

As a "public shell" company with no active research, development, or commercial operations, SYNLOGIC, INC. no longer holds a competitive position within the biopharmaceutical industry or any other specific market for goods or services.

• Former Market: The company exited its competitive position in the rare metabolic disorders biopharmaceutical market by ceasing all drug development activities.
• Current "Competition": Its current "competitive landscape" is limited to the market for strategic transactions. Here, it competes with other public and private entities seeking mergers, acquisitions, or other corporate actions. Its primary competitive advantage in this context is its status as a publicly traded entity.

Risk Factors

SYNLOGIC, INC. faces substantial risks and an uncertain future.

• Failure to Execute Strategic Transaction: The most significant risk is the inability to identify or successfully complete a strategic transaction that delivers value to shareholders. If no suitable transaction is found, the company may eventually liquidate its remaining assets, potentially resulting in little to no recovery for shareholders.
• Going Concern Risk: While current cash reserves exist, the company's ability to continue as a going concern depends on successfully executing a strategic transaction or securing additional funding, which is not guaranteed.
• Liquidity and Volatility of OTC Trading: Trading on the Pink Sheets carries increased risks, including lower trading volume, wider bid-ask spreads, and greater price volatility. This makes it difficult for investors to buy or sell shares at desired prices.
• Dilution Risk: Any strategic transaction, particularly a reverse merger or acquisition, could involve issuing new shares, potentially leading to significant dilution for existing shareholders.
• Competition for Strategic Opportunities: The market for "public shell" companies is competitive. SYNLOGIC, INC. has no assurance it will attract a desirable partner or transaction.
• Loss of Key Personnel: Despite significant workforce reductions, the company relies on a small team to manage its public company obligations and strategic process. Losing any key personnel could adversely affect its ability to execute its strategy.
• Regulatory and Compliance Risks: Maintaining public company status, even as a shell, involves significant regulatory compliance costs and risks. Failure to comply with SEC reporting requirements could lead to further delisting or penalties.

In summary, SYNLOGIC, INC. has transitioned from a biopharmaceutical developer to a "public shell" company with no active operations, minimal employees, and no revenue. Its future hinges entirely on successfully executing a strategic transaction, an outcome that remains highly uncertain and carries significant risks for investors.